Poseida Therapeutics is a clinical-stage biopharmaceutical company that develops gene therapies for orphan diseases. The company's proprietary technology platform, piggyBac, is a non-viral gene delivery system that enables the creation of stable cell lines that can be used to produce therapeutic proteins. Poseida's lead product candidate, P-BCMA-ALLO1, is a CAR-T cell therapy for the treatment of multiple myeloma. The company was founded in 2014 and is headquartered in San Diego, California.